Metastatic Pancreatic Cancer: ASCO Guideline Update
Top Cited Papers
- 20 September 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 38 (27), 3217-3230
- https://doi.org/10.1200/jco.20.01364
Abstract
The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatment-eligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.This publication has 23 references indexed in Scilit:
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based ChemotherapyJournal of Clinical Oncology, 2016
- Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2016
- Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2016
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 TrialJournal of Clinical Oncology, 2014
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trialsAnnals of Oncology, 2013
- Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementabilityJournal of the American Medical Informatics Association, 2012
- PALB2 mutations in familial breast and pancreatic cancerFamilial Cancer, 2011
- Grading quality of evidence and strength of recommendations in clinical practice guidelines Part 3 of 3. The GRADE approach to developing recommendationsAllergy, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- How Quickly Do Systematic Reviews Go Out of Date? A Survival AnalysisAnnals of Internal Medicine, 2007